Quick Answer
Akebia Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $184.84 million for the year ending 2025.
- Akebia Therapeutics, Inc. showed an increase of +256.4% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Akebia Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), Akebia Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 3,588.8%.
- Historical annual values: Fiscal year 2025: $184.84 million | Fiscal year 2024: $51.87 million | Fiscal year 2023: $42.93 million | Fiscal year 2022: $90.47 million | Fiscal year 2021: $149.80 million | Fiscal year 2020: $228.70 million | Fiscal year 2019: $147.45 million | Fiscal year 2018: $104.64 million | Fiscal year 2017: $70.16 million | Fiscal year 2016: $187.34 million | Fiscal year 2015: $49.78 million | Fiscal year 2014: $32.78 million | Fiscal year 2013: $21.22 million | Fiscal year 2012: $1.64 million | Fiscal year 2011: $5.01 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: